The National Institute for Health and Care Excellence (NICE) concluded that CAR-T is too expensive to recommend as a treatment for adults with lymphoma. However, NICE does recognize that Novartis’ tisagenlecleucel-T, also known as Kymriah, has significant clinical benefits, and would welcome further discussions on its cost-effectiveness. NICE’s independent technology appraisal committee considered tisagenlecleucel-T for…